Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Total Non-Current Liabilities: 2013-2024

Historic Total Non-Current Liabilities for ImmunityBio (IBRX) over the last 9 years, with Dec 2024 value amounting to $844.9 million.

  • ImmunityBio's Total Non-Current Liabilities fell 14.89% to $927.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $927.2 million, marking a year-over-year decrease of 14.89%. This contributed to the annual value of $844.9 million for FY2024, which is 13.04% down from last year.
  • As of FY2024, ImmunityBio's Total Non-Current Liabilities stood at $844.9 million, which was down 13.04% from $971.6 million recorded in FY2023.
  • In the past 5 years, ImmunityBio's Total Non-Current Liabilities ranged from a high of $971.6 million in FY2023 and a low of $338.8 million during FY2020.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $844.9 million (2024), whereas its average is $869.0 million.
  • Per our database at Business Quant, ImmunityBio's Total Non-Current Liabilities spiked by 110.25% in 2021 and then decreased by 13.04% in 2024.
  • ImmunityBio's Total Non-Current Liabilities (Yearly) stood at $338.8 million in 2020, then spiked by 110.25% to $712.4 million in 2021, then grew by 10.97% to $790.5 million in 2022, then rose by 22.91% to $971.6 million in 2023, then decreased by 13.04% to $844.9 million in 2024.